Allergy Therapeutics plc Disruptive peanut allergy vaccine

Hardman & Co ReportAllergy Therapeutics plc (LON:AGY) is a long-established specialist in the prevention, diagnosis and treatment of allergies. Trials to obtain full regulatory approval as a biological for its ultra short-course immunotherapy, Pollinex Quattro, have progressed well in the EU, and are back on-track in the US with a planned new safety trial. Meanwhile, AGY acquired novel virus-like particle (VLP) technology with the goal to develop a short-course therapeutic vaccine for peanut allergy. Positive safety and efficacy results from proof-of-concept pre-clinical tests with Polyvac Peanut are very encouraging. A small safety study in humans is required before Phase I trials can commence.

 
Peanut allergy: Peanut allergy has emerged over the last 40 years and it is thought that there are an estimated 4 million sufferers in the US alone, of which 2-3 million are children. Peanut allergy is the number one cause of death from food reactions.

VLP technology: Although Allergy is one of the leading global authorities in immunotherapies against a number of allergens, it did not have anything in its armoury for peanut allergy. Therefore, in November 2015, it acquired a licence to develop novel VLP technology for use as an adjuvant for a peanut vaccine.

Proof-of-concept: AGY has made rapid progress over the last 15 months, identifying a lead VLP adjuvant and combining it with recombinant peanut allergen to create a single dose, subcutaneously administered, therapeutic vaccine which has given positive safety and efficacy results in pre-clinical tests.

Next steps: The company will enter discussions with the regulator about recruitment of patients into a required small safety study with Polyvac Peanut. This preludes commencement of Phase I development, in-line with the strategic development plan provided at the time of the last funding round.

Investment summary: Allergy Therapeutics plc is well positioned to benefit from the change in regulatory attitude towards therapeutic allergy vaccines, particularly in the US where the market is largely unregulated. Meanwhile it is expanding its expertise in short-course immunotherapy into areas of unmet medical need and Polyvac Peanut has the potential to disrupt the current $8bn peanut allergy market.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
X
LinkedIn
Hardman & Co

More articles like this

Allergens dominate UK food recalls, finds study

More than half of food recalls in the United Kingdom over a 5-year period were due to allergens, according to a recently released study. Allergen-related recalls increased annually until 2019, peaking at 118 before decreasing to

Allergy Therapeutics welcomes new Non-Executive Directors

Allergy Therapeutics announced the appointments of Anthony Parker and Simon Shen to its Board as Non-Executive Directors effective immediately. “I would like to welcome Anthony and Simon. Southern Fox and ZQ Capital have been long-standing and supportive shareholders of Allergy

Allergy Therapeutics updates on its clinical programmes

Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, has announced that the first subject has been dosed in the pivotal Phase III G306 trial, to evaluate the efficacy and safety of

Allergy Therapeutics appoints two Non-Executive Directors

Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, has today announced the appointments of Anthony Parker and Zheqing (Simon) Shen as Non-Executive Directors of the Company, with immediate effect. Anthony represents

Allergies and Thanksgiving

As Thanksgiving and other holiday celebrations bring people around the table, Intermountain Healthcare dietitians say it’s crucial to take food allergies into consideration when planning the big meal. “A response to an allergic reaction can be

Allergy Therapeutics appoints Martin Hopcroft as interim CFO

Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, has announced the appointment of Martin Hopcroft to the role of Interim Chief Financial Officer (CFO). Martin will report into Chief Executive

Food business operator fined for allergy breach

A food business operator based in Newcastle, England has been fined in court after serving a dish containing peanuts to a woman with a peanut allergy, resulting in her being hospitalised. According to the Food Standards

Are restaurants taking allergies seriously?

In an engaging panel held at Twickenham Stadium as part of New Food’s Food Safety Conference 2022, experts came together to debate whether food allergy regulations in restaurants are sufficient. Here’s the highlights. Are restaurant allergy

Allergy Therapeutics Subscription to raise £7 million

Allergy Therapeutics plc (LON:AGY), the fully integrated specialty pharmaceutical company specialising in allergy immunotherapy, today announces a conditional Subscription by the Subscribers, Southern Fox and ZQ Capital (acting through its affiliate SkyGem), to raise £7 million